Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids

Molecular Therapy

Volumn 3, Issue 6, 2001, Pages 964-975

  Grifman, Mirta ^a   Trepel, Martin ^b   Speece, Paul ^a,c   Gilbert, Luz Beatriz ^a   Arap, Wadih ^b   Pasqualini, Renata ^b   Weitzman, Matthew D ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HEPARIN; MICROSOMAL AMINOPEPTIDASE; MUTANT PROTEIN; PEPTIDE; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANGIOGENESIS; ARTICLE; CELL TYPE; CONTROLLED STUDY; DNA MODIFICATION; DNA PACKAGING; DRUG TARGETING; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENE SEQUENCE; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HOST; IN VIVO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE MYC; PHAGE DISPLAY; PROTEIN ISOLATION; PROTEIN MOTIF; RECEPTOR BINDING; TRANSGENE; TUMOR CELL LINE; VASCULARIZATION; VIRUS CAPSID; VIRUS RECOMBINANT;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS 2; MIRIDAE; PARVOVIRUS;

EID: 0034963928     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2001.0345     Document Type: Article

References (65)

1. AAV vectors: Is clinical success on the horizon?
2. Adeno-associated virus vector-mediated gene transfer to somatic cells in the central nervous system
3. Gene transfer by adeno-associated virus vectors into the central nervous system
4. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
5. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector
6. Recombinant adeno-associated virus for muscle directed gene therapy
7. Transduction by adeno-associated virus vectors in the rabbit airway: Efficiency, persistence, and readministration
8. + hematopoietic progenitor cells: Donor variation and correlation of transgene expression with cellular differentiation
9. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody
10. Adeno-associated virus type 2 binds to a 150-kilodalton cell membrane glycoprotein
11. Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: Human megakaryocytic leukaemia AAV infection
12. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions
13. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
14. AlphaVbeta5 integrin: A co-receptor for adeno-associated virus type 2 infection
15. Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation
16. Dynamin is required for recombinant adeno-associated virus type 2 infection
17. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors
18. Recruitment of wild-type and recombinant adeno-associated virus into adenovirus replication centers
19. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts
20. Molecular biology of the adeno-associated viruses
21. Cloning of infectious adeno-associated virus genomes in bacterial plasmids
22. Cloning of adeno-associated virus into pBR322: Rescue of intact virus from the recombinant plasmid in human cells
23. Parvoviridae: The viruses and their replication
24. Synthesis of adeno-associated virus structural proteins requires both alternative mRNA splicing and alternative initiations from a single transcript
25. The three-dimensional structure of canine parvovirus and its functional implications
26. Structure determination of feline panleukopenia virus empty particles
27. Functional implications of the structure of the murine parvovirus, minute virus of mice
28. The structure of human parvovirus B19 at 8 A resolution
29. Structure, sequence, and function correlations among parvoviruses
30. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: Epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection
31. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: Implications for gene therapy and virus structure
32. Building a better vector: The manipulations of AAV virions
33. Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy
34. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
35. Insertional mutagenesis of AAV2 capsid and the production of recombinant virus
36. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism
37. Organ targeting in vivo using phage display peptide libraries
38. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display
39. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
40. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis
41. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)
42. Tumor targeting with a selective gelatinase inhibitor
43. Role for highly regulated rep gene expression in adeno-associated virus vector production
44. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus
45. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield
46. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses
47. Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3
48. Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses
49. Gene therapy vectors based on adeno-associated virus type 1
50. Cloning and characterization of adeno-associated virus type 5
51. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2
52. B-cell epitopes of canine parvovirus: Distribution on the primary structure and exposure on the viral surface
53. Two dominant neutralizing antigenic determinants of canine parvovirus are found on the threefold spike of the virus capsid
54. A second neutralizing epitope of B19 parvovirus implicates the spike region in the immune response
55. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading strand synthesis
56. Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display
57. Elucidation of muscle-binding peptides by phage display screening
58. NG2 proteoglycan-binding peptides target tumor neovasculature
59. Chemotherapy targeted to tumor vasculature
60. Molecular adaptors for vascular-targeted adenoviral gene delivery
61. Identification of domains in canine parvovirus VP2 essential for the assembly of virus-like particles
62. The interaction of heparin sulfate and adeno-associated virus 2
63. Integrin alphaVbeta5 is not involved in adeno-associated virus type 2 (AAV2) infection
64. Adeno-associated virus 2 co-receptors?
65. Host range and variability of calcium binding by surface loops in the capsids of canine and feline parvoviruses